Clinical Trials /

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1

NCT02775292

Description:

This phase I trial studies the side effects and the best dose of nivolumab when given together with gene-modified T cells and vaccine therapy in treating patients with solid tumors that express the cancer-testes antigen NY-ESO-1 gene AND have spread from where it started to nearby tissue or lymph nodes (locally advanced) or distant organs (stage IV). T cells are a special type of white blood cells (immune cell) that have the ability to kill cancer cells. Nivolumab may block PD-1 which is found on T cells and help the immune system kill cancer cells. Placing a modified gene for the NY-ESO-1 T cell receptor (TCR) into the patients' T cells in the laboratory and then giving them back to the patient may help the body build an immune response to kill tumor cells that express NY-ESO-1. Dendritic cells are another type of blood cell that can teach other cells in the body to look for cancer cells and attack them. Giving a dendritic cell vaccine with the NY-ESO-1 protein may help dendritic cells teach the immune system to target cancer cells expressing that protein, and further help the T cells attack cancer. Giving nivolumab together with gene-modified T-cells and dendritic cell vaccine may teach the immune system to recognize and kill cancer cells that express NY-ESO-1.

Related Conditions:
  • Malignant Solid Tumor
Recruiting Status:

Completed

Phase:

Phase 1

Trial Eligibility

Document

Title

  • Brief Title: Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1
  • Official Title: NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With Nivolumab PD-1 Blockade

Clinical Trial IDs

  • ORG STUDY ID: 15-001433
  • SECONDARY ID: NCI-2016-00201
  • SECONDARY ID: Ribas NYESO + Nivolumab Cancer
  • SECONDARY ID: 15-001433
  • SECONDARY ID: P30CA016042
  • NCT ID: NCT02775292

Conditions

  • Adult Solid Neoplasm
  • Childhood Solid Neoplasm
  • Metastatic Neoplasm

Interventions

DrugSynonymsArms
Aldesleukin125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2Treatment (NY-ESO-1 TCR transduced PBMC, vaccine, nivolumab)
Cyclophosphamide(-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719Treatment (NY-ESO-1 TCR transduced PBMC, vaccine, nivolumab)
Fludarabine Phosphate2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, Oforta, SH T 586Treatment (NY-ESO-1 TCR transduced PBMC, vaccine, nivolumab)
NivolumabBMS-936558, MDX-1106, NIVO, ONO-4538, OpdivoTreatment (NY-ESO-1 TCR transduced PBMC, vaccine, nivolumab)
NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBLAnti-NY-ESO-1 TCR Retroviral Vector Transduced Autologous PBLTreatment (NY-ESO-1 TCR transduced PBMC, vaccine, nivolumab)
NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell VaccineAutologous NY-ESO-1 (157-165) Peptide-pulsed DC VaccineTreatment (NY-ESO-1 TCR transduced PBMC, vaccine, nivolumab)

Purpose

This phase I trial studies the side effects and the best dose of nivolumab when given together with gene-modified T cells and vaccine therapy in treating patients with solid tumors that express the cancer-testes antigen NY-ESO-1 gene AND have spread from where it started to nearby tissue or lymph nodes (locally advanced) or distant organs (stage IV). T cells are a special type of white blood cells (immune cell) that have the ability to kill cancer cells. Nivolumab may block PD-1 which is found on T cells and help the immune system kill cancer cells. Placing a modified gene for the NY-ESO-1 T cell receptor (TCR) into the patients' T cells in the laboratory and then giving them back to the patient may help the body build an immune response to kill tumor cells that express NY-ESO-1. Dendritic cells are another type of blood cell that can teach other cells in the body to look for cancer cells and attack them. Giving a dendritic cell vaccine with the NY-ESO-1 protein may help dendritic cells teach the immune system to target cancer cells expressing that protein, and further help the T cells attack cancer. Giving nivolumab together with gene-modified T-cells and dendritic cell vaccine may teach the immune system to recognize and kill cancer cells that express NY-ESO-1.

Detailed Description

      PRIMARY OBJECTIVES:

      I. To determine the safety of the addition of the PD-1 blocking monoclonal antibody,
      nivolumab, to NY-ESO TCR-transduced autologous peripheral blood lymphocyte (PBL) adoptive
      cell transfer (ACT) in a dose escalation scheme in two study cohorts at 1 mg/kg and 3 mg/kg
      of nivolumab intravenous (i.v.) every two weeks for up to 2 years.

      SECONDARY OBJECTIVES:

      I. To determine the feasibility of delivering the TCR transgenic cell dose and PD-1 blockade
      to patients.

      II. To determine the persistence of NY-ESO-1 TCR-engineered peripheral blood mononuclear cell
      (PBMC) in serial peripheral blood samples and in biopsies of accessible metastatic lesions.

      EXPLORATORY OBJECTIVES:

      I. To determine whether blocking PD-1 will maintain the antitumor functionality of adoptively
      transferred TCR transgenic lymphocytes.

      II. To explore the use of positron emission tomography (PET)-based imaging using the PET
      tracer (18F) fluorodeoxy-glucose ([18F]FDG) with the goal of determining if the adoptively
      transferred NY-ESO-1 TCR-engineered PBMC when administered with nivolumab home and expand in
      secondary lymphoid organs and tumor deposits.

      III. Clinical antitumor activity recording objective response rate.

      OUTLINE: This is a dose-escalation study of nivolumab.

      CONDITIONING REGIMEN: Patients receive cyclophosphamide intravenously (IV) over 1 hour on
      days -5 to -4 and fludarabine phosphate IV over 15-30 minutes on days -4 to -1.

      NY-ESO-1 TCR PBMC INFUSION: Patients receive NY-ESO-1 TCR PBMC IV on day 0.

      NIVOLUMAB: Patients receive nivolumab IV over 60 minutes on day 0 or 1. Treatment repeats
      every 2 weeks for up to 2 years in the absence of disease progression or unacceptable
      toxicity.

      NY-ESO-1(157-165) PEPTIDE PULSED DENDRITIC CELL (DC): Patients receive NY-ESO-1(157-165)
      peptide pulsed DC intradermally (ID) on days 1, 14, and 28.

      LOW DOSE ALDESLEUKIN ADMINISTRATION: Patients receive aldesleukin subcutaneously (SC) twice
      daily (BID) for 7 days beginning on day 1 for a maximum of 14 doses.

      After completion of study treatment, patients are followed up at least every 6 months for 3
      years and then at least every 12 months for up to 15 years.
    

Trial Arms

NameTypeDescriptionInterventions
Treatment (NY-ESO-1 TCR transduced PBMC, vaccine, nivolumab)ExperimentalCONDITIONING REGIMEN: Patients receive cyclophosphamide IV over 1 hour on days -5 to -4 and fludarabine phosphate IV over 30 minutes on days -4 to -1. NY-ESO-1 TCR PBMC INFUSION: Patients receive NY-ESO-1 TCR PBMC IV on day 0. NIVOLUMAB: Patients receive nivolumab IV over 60 minutes on day 0 or 1. Treatment repeats every 2 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. NY-ESO-1(157-165) PEPTIDE PULSED DC: Patients receive NY-ESO-1(157-165) peptide pulsed DC ID on days 1, 14, and 28. LOW DOSE ALDESLEUKIN ADMINISTRATION: Patients receive aldesleukin SC BID for 7 days beginning on day 1 for a maximum of 14 doses.
  • Aldesleukin
  • Cyclophosphamide
  • Fludarabine Phosphate
  • Nivolumab
  • NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL
  • NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine

Eligibility Criteria

        Inclusion Criteria:

          -  Stage IV or locally advanced histologically confirmed solid tumors for which no
             alternative therapies with proven survival advantage are available

          -  At least 1 lesion amenable for outpatient biopsies; this should be a cutaneous or
             palpable metastatic site or a deeper site accessible by image-guided biopsy that is
             deemed safe to access by the treating physicians and interventional radiologists;
             patients without accessible lesions for biopsy but with prior tissue available from
             metastatic disease would be eligible at the investigator's discretion

          -  NY-ESO-1 positive malignancy by immunohistochemistry (IHC) utilizing commonly
             available NY-ESO-1 antibodies

          -  Human leukocyte antigen (HLA)-A*0201 (HLA-A2.1) positivity by molecular subtyping

          -  Age greater than or equal to 16 years old

          -  A minimum of one measurable lesion defined as:

               -  Meeting the criteria for measurable disease according to Response Evaluation
                  Criteria In Solid Tumors (RECIST)

               -  Skin lesion(s) selected as non-completely biopsied target lesion(s) that can be
                  accurately measured and recorded by color photography with a ruler to document
                  the size of the target lesion(s)

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

          -  Absolute neutrophil count >= 1.5 x 10^9 cells/L

          -  Platelets >= 100 x 10^9/L

          -  Hemoglobin >= 9 g/dL

          -  Aspartate and alanine aminotransferases (AST, ALT) =< 2.5 x upper limit of normal
             (ULN) (=< 5 x ULN, if documented liver metastases are present)

          -  Total bilirubin =< 2 x ULN (except patients with documented Gilbert's syndrome)

          -  Creatinine < 2 mg/dl (or a glomerular filtration rate > 60)

          -  Must be willing and able to accept two leukapheresis procedures

          -  Must be willing and able to provide written informed consent

        Exclusion Criteria:

          -  Previously known hypersensitivity to any of the agents used in this study

          -  Received systemic treatment for cancer, including immunotherapy, within one month
             prior to initiation of dosing within this protocol

          -  History of, or significant evidence of risk for, chronic inflammatory or autoimmune
             disease (eg, Addison's disease, multiple sclerosis, Graves disease, Hashimoto's
             thyroiditis, inflammatory bowel disease, psoriasis, rheumatoid arthritis, systemic
             lupus erythematosus, hypophysitis, pituitary disorders, etc.); patients will be
             eligible if prior autoimmune disease is not deemed to be active (e.x. fibrotic damage
             of the thyroid after thyroiditis or its treatment, with stable thyroid hormone
             replacement therapy); vitiligo will not be a basis for exclusion

          -  History of inflammatory bowel disease, celiac disease, or other chronic
             gastrointestinal conditions associated with diarrhea or bleeding, or current acute
             colitis of any origin

          -  Potential requirement for systemic corticosteroids or concurrent immunosuppressive
             drugs based on prior history or received systemic steroids within the last 2 weeks
             prior to enrollment (inhaled or topical steroids at standard doses are allowed)

          -  Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired
             immune deficiency state; if there is a positive result in the infectious disease
             testing that was not previously known, the patient will be referred to their primary
             physician and/or infectious disease specialist

          -  Hepatitis B or C seropositivity with evidence of ongoing liver damage; if there is a
             positive result in the infectious disease testing that was not previously known, the
             patient will be referred to their primary physician and/or infectious disease
             specialist

          -  Dementia or significantly altered mental status that would prohibit the understanding
             or rendering of informed consent and compliance with the requirements of this protocol

          -  Known clinically active brain metastases; prior evidence of brain metastasis
             successfully treated with surgery or radiation therapy will not be exclusion for
             participation as long as they are deemed under control at the time of study enrollment
             and there are no neurological signs of potential brain metastases

          -  Pregnancy or breast-feeding; female patients must be surgically sterile or be
             postmenopausal for two years, or must agree to use effective contraception during the
             period of treatment and 6 months after; all female patients with reproductive
             potential must have a negative pregnancy test (serum/urine) within 24 hours from
             starting the conditioning chemotherapy; the definition of effective contraception will
             be based on the judgment of the study investigators; patients who are breastfeeding
             are not allowed on study

          -  Since IL-2 is administered following cell infusion:

               -  Patients will be excluded if they have a history of clinically significant
                  electrocardiogram (ECG) abnormalities, symptoms of cardiac ischemia or
                  arrhythmias and have a left ventricular ejection fraction (LVEF) < 45% on a
                  cardiac stress test (stress thallium, stress multi gated acquisition scan [MUGA],
                  dobutamine echocardiogram, or other stress test)

               -  Similarly, patients who are >= 50 years old with a baseline LVEF < 45% will be
                  excluded

               -  Patients with ECG results of any conduction delays (PR interval > 200 ms,
                  corrected QT interval [QTC] > 480 ms), sinus bradycardia (resting heart rate < 50
                  beats per minute), sinus tachycardia (heart rate > 120 beats per minute) will be
                  evaluated by a cardiologist prior to starting the trial; patients with any
                  arrhythmias, including atrial fibrillation/atrial flutter, excessive ectopy
                  (defined as > 20 premature ventricular contractions [PVCs] per minute),
                  ventricular tachycardia, third (3rd) degree heart block will be excluded from the
                  study unless cleared by a cardiologist

               -  Patients with pulmonary function test abnormalities as evidenced by a forced
                  expiration volume in one second (FEV1)/forced vital capacity (FVC) < 70% of
                  predicted for normality will be excluded

          -  Evidence of diverticulitis at baseline, including evidence limited to computed
             tomography (CT) scan only

          -  Received 3 or more prior myelotoxic treatment regimens

          -  Bone marrow involvement based on CT or PET scan at screening
      
Maximum Eligible Age:N/A
Minimum Eligible Age:16 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Incidence of adverse events, defined following the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
Time Frame:Up to 15 years
Safety Issue:
Description:Simple descriptive statistics will be used to summarize toxicities observed after TCR transgenic cell infusion in terms of type (organ affected or laboratory determination such as absolute neutrophil count), severity and nadir or maximum values for the laboratory measures, time of onset (i.e. course number), duration, and reversibility or outcome. Tables will be created to summarize these toxicities and side effects by dose and by course.

Secondary Outcome Measures

Measure:Feasibility of generating NY-ESO-1 TCR cells and/or NY-ESO 1(157-165) peptide pulsed DC vaccine, determined by the incidence of preparation not meeting the lot release criteria
Time Frame:1 month
Safety Issue:
Description:Descriptive statistics including simple summary measures and plots appropriate for longitudinal data will be used.
Measure:Transgenic cell persistence
Time Frame:Up to 15 years
Safety Issue:
Description:Analysis will be performed both using immune monitoring and molecular techniques. Detection of surface expression of the NY-ESO-1 TCR transgenic protein will be analyzed both by major histocompatibility complex tetramer or dextramer analysis and staining for the specific region. Molecular analysis of the persistence of cells bearing the NY-ESO-1 TCR complementary deoxyribonucleic acid will be done by real time polymerase chain reaction techniques using primers specific for the transgenes and retroviral vector sequences. This testing will provide data to estimate the in vivo survival of lymphoc

Details

Phase:Phase 1
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Jonsson Comprehensive Cancer Center

Last Updated